Personalised to support your treatment decisions
Helsinn and MEI Pharma have discontinued a Phase III trial of SB 393 (pracinostat) in combination with Vidaza (azacitidine) in patients with acute myeloid leukaemia (AML) who are unsuitable for standard intensive chemotherapy.
Hansa Biopharma the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced that it has entered into an agreement with Sarepta Therapeutics Inc., the leader in precision genetic medicine for rare diseases, through which Sarepta is granted an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD).
Mezzion Pharma has submitted a New Drug Application (NDA) to the FDA for udenafil to improve the physiology of patients aged at least 12 years with single ventricle heart disease (SVHD) who have undergone the Fontan operation.
You may be interested in...
6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation.
The Haematological Tumour Microenvironment and its Therapeutic Targeting 2021
This workshop brings together a constantly growing and international community of researchers, physicians and physician scientists, as well as biologists and physicians in training and corporate representatives, whose present or future work is focused on the tumor microenvironment in the haematological malignancies.